202 results about "Systemic toxicity" patented technology

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

The invention provides a microneedle preparation for co-delivering photo-thermal nano-enzyme and elemene as well as a preparation method and application of the microneedle preparation. The preparation method comprises the following steps: firstly, preparing a novel photo-thermal nano enzyme Au (at) MoS2 through a two-step water phase synthesis strategy; benefited from the synergistic effect of the hybrid material, the nano-enzyme shows significantly enhanced near-infrared (NIR) photothermal effect, peroxidase-like (POD) activity and glutathione-like peroxidase (GSHOx) activity, and can effectively remodel the tumor microenvironment and destroy the redox steady state. Furthermore, photo-thermal nano enzyme, beta-ELE and hyaluronic acid are used as raw materials, and a novel soluble microneedle preparation is successfully prepared through a template method. The novel composite microneedle is in a sharp rectangular pyramid shape, growth of melanoma can be effectively inhibited through percutaneous delivery of photo-thermal nano-enzyme and beta-ELE, remarkable systemic toxicity is avoided, and an innovative strategy is provided for non-invasive, efficient and safe melanoma combined treatment.

The invention relates to a Cu2-xSe-Pt nano material, a microneedle patch, a preparation method and application. The Cu < 2-x > Se (at) Pt nano material is composed of a Cu < 2-x > Se nanosphere and platinum modified on the surface of the Cu < 2-x > Se nanosphere in situ. The invention provides a preparation method of a Cu2-xSe-Pt nano-material, which comprises the following steps: adding PSS, SeO2 and AA into water, heating and stirring, adding copper salt and AA, reacting, and adding water and a hexachloroplatinic acid solution to obtain the Cu2-xSe-Pt nano-material. The invention provides an application of a Cu < 2-x > Se (at) Pt nano material. The invention also provides a microneedle patch as well as a preparation method and application thereof. The invention provides a novel material for resisting multi-drug-resistant bacteria, which solves the problems that the existing single antibacterial strategy is limited and the expected curative effect cannot be achieved, also solves the problem of cytotoxicity of the existing nano enzyme, realizes deep drug delivery, ensures efficient local drug release and avoids systemic toxicity.

The invention discloses a nano-enzyme microneedle system for remodeling a diabetes wound microenvironment to promote healing and a preparation method of the nano-enzyme microneedle system. The nano-enzyme microneedle system comprises nano-enzyme and a microneedle carrier, the nano-enzyme is prepared by a self-assembly method and is loaded in the microneedle carrier; the microneedle carrier is composed of a hydrogel matrix and is molded into a microneedle array through 3D printing; according to the system, the nano-enzyme can be delivered to the corium layer by penetrating the cuticle of the skin through the microneedle. The traditional Chinese medicine composition has the advantages that ROS (reactive oxygen species) is efficiently removed, oxidative stress injury induced by high glucose (HG) is relieved, immune cell polarization is regulated, inflammatory factor release is regulated and controlled, the chronic inflammation state of wound surfaces is relieved, cell proliferation and migration are promoted, neovascularization is accelerated, the healing speed of the diabetic wound surfaces is obviously increased, inflammation infiltration is reduced, granulation tissue formation and collagen deposition are obviously improved, and the effect of treating diabetes mellitus is achieved. And no systemic toxicity is observed. Through the synergistic effect of resisting oxidation, resisting inflammation and promoting angiogenesis, the pathological microenvironment of the diabetic wound is effectively improved.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to lidocaine multivesicular liposome as well as a preparation method and application thereof, belongs to the field of medicines, and solves at least one of the problems of higher toxicity, insufficient safety, short action time, limited clinical application range, higher cost and the like of the existing postoperative analgesic medicine. The lidocaine multi-vesicular liposome is prepared from lidocaine and a lipid, wherein the lidocaine and the lipid are added into the lidocaine multi-vesicular liposome; the lipid comprises amphiphilic lipid, negatively charged phospholipid, neutral lipid and cholesterol. The lidocaine multi-vesicular liposome prepared by the preparation method is high in safety, solves the problems of systemic toxicity, neurotoxicity, cardiotoxicity and the like of the existing postoperative analgesic drugs, has the characteristics of long-acting slow release, remarkable analgesic effect and wide clinical application range, and is suitable for clinical application. And a new solution is provided for effectively relieving postoperative pain.

The invention provides a nano-drug carrier and a drug release system, the nano-drug carrier comprises a drug loading core and a responsive shell arranged outside the drug loading core, and the drug loading core is loaded with a nano-drug; the surface of the responsive shell is modified with a targeting ligand, and the targeting ligand can specifically target pain-related cells or tissues. According to the nano-drug carrier and the drug release system provided by the invention, precise long-acting treatment of chronic pain is realized through combination of an environment-responsive carrier and an active targeting technology. The technology can significantly improve local accumulation of the medicine and reduce systemic toxicity, and is suitable for management of intractable pains such as neuropathic pains and osteoarthritis.

The invention discloses a methotrexate-cationic polypeptide conjugate as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. According to the conjugate, MTX and cationic polypeptide with the amino acid sequence shown as SEQ ID NO: 1 are connected through chemical bonding, the membrane binding characteristic of oligomeric lysine and the transmembrane capacity of TAT cell-penetrating peptide are creatively fused, and a polypeptide carrier system with efficient cell penetrating capacity is constructed; mTX obtains amphipathy and electropositivity through peptide fragment modification, stable nanoparticles can be spontaneously formed, and the problems of poor water solubility and instable acidity of raw material medicines are effectively improved; according to the conjugate, the accumulation efficiency of the medicine at a diseased region is remarkably improved by utilizing the targeting characteristic of the polypeptide carrier, the action time of the medicine is prolonged through a precise delivery mechanism, and meanwhile, the system toxicity is reduced. The preparation method adopts mild coupling reaction conditions, and the product is high in purity and excellent in stability; the compound is suitable for treating immune-mediated inflammatory diseases and specific malignant tumors, and provides an innovative solution thought for treating related diseases.

Provided herein are locoregional therapies using conjugates of therapeutic agents that demonstrate extended release of the native therapeutic agents, as well as methods for the manufacture of such conjugates. These conjugates may be useful in the treatment of various conditions and diseases that respond to the extended exposure to the therapeutic agents, or for delivery of therapeutic agents that suffer from undesired systemic toxicities. In certain embodiments, the locoregional therapy is intratumoral therapy, which may be combined with a systemic or local therapy for enhanced therapeutic efficacy and reduced toxicity of the combined agents.

The invention provides a smearing sustained-release preparation and a preparation method and application thereof, the smearing sustained-release preparation comprises a chemotherapeutic drug component, an immune drug component and a sustained-release auxiliary material, and the smearing sustained-release preparation is in a transparent flowable sol shape. The sustained release preparation disclosed by the invention can be smeared and applied to a focus part in situ after a tumor operation. The application effect comprises the following steps: filling the treatment window period of the traditional postoperative adjuvant chemotherapy, and improving the local drug concentration of the focus through in-situ local slow release of the drug, thereby effectively removing residual tumor tissues and reducing the systemic toxicity of drug treatment; the metastasis and recurrence rate of tumors are further inhibited through the synergistic combined effect of chemotherapy-immune drugs in the preparation. The advantages show that the smearing sustained-release preparation provided by the invention has huge clinical potential in the aspect of tumor treatment.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The present invention relates to the technical field of tumor therapeutic drugs, and in particular to a composition of albumin and mercaptododecaborane and its application in the preparation of tumor therapeutic drugs. Its technical solution includes albumin, which is covalently coupled with mercaptododecaborane through the cysteine thiol group at position 34 to construct a nucleation site, and further point-loaded with mercaptododecaborane on the protein through the nucleation effect; the thiol group of the mercaptododecaborane is bound to the thiol group at position 34 of albumin cysteine through a disulfide bond. The present invention forms a nucleus by covalently coupling the free thiol group of albumin with mercaptododecaborane, and utilizes the nucleation effect to point-coat mercaptododecaborane, thereby avoiding the toxicity risks brought by organic solvents or chemical modifications in traditional solubilization methods, and effectively preventing oxidative degradation and free boron ion release, achieving pH-responsive targeted release, and significantly increasing the boron accumulation in tumor tissues, with both high stability, precise drug release, and low systemic toxicity.

The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.

The invention discloses a glucan-based MMAE conjugate as well as a preparation method and application thereof, and relates to the technical field of medicines. The conjugate takes glucan with good biocompatibility as a carrier, and is covalently connected with a cytotoxic drug MMAE through a VC peptide linker capable of being cut by cathepsin B. The conjugate has good serum stability, can specifically release drugs at a tumor site, and realizes efficient tumor uptake by virtue of the stealth effect of glucan and potential GLUT1 targeting. In-vitro and animal experiments show that the conjugate has a remarkable treatment effect on pancreatic cancer and is low in systemic toxicity.

The invention relates to the technical field of biological pharmacy, in particular to an application of N-[(3-chlorphenyl) methyl]-5-methyl-4-[(morpholine-4-yl) methyl]-1, 2-azole-3-formamide in preparation of an anti-melanoma drug and a preparation method of the N-[(3-chlorphenyl) methyl]-5-methyl-4-[(morpholine-4-yl) methyl]-1, 2-azole-3-formamide. According to the invention, specific pharmacophore and hydrophobic / hydrophilic modification are introduced in structure, so that the combination selectivity and stability of the compound and a target spot are improved; on the action mechanism, the compound can effectively interfere with a Bcl-3 signal channel. In-vivo experiments prove that the compound disclosed by the invention has a good tumor inhibition effect in an animal model, meanwhile, no obvious systemic toxicity is observed, and a relatively high therapeutic index is shown. In addition, the compound has good physicochemical properties and synthesis process feasibility, is convenient for industrial production, and is expected to become a novel candidate drug for clinical melanoma resistance.

The invention discloses a surface drug-loaded multifunctional engineering probiotic with antigen capture capability, a preparation method and application, the strain takes non-pathogenic probiotic as an original strain, after the engineering probiotic expressing protein stimulating immune cell development or differentiation is constructed, the surface of the engineering probiotic is modified with maleimide functional groups and drug-loaded nano-particles, and the surface drug-loaded multifunctional engineering probiotic with antigen capture capability is obtained. Therefore, the compound is a multifunctional bacterium with antigen capture, drug delivery and anti-tumor effects at the same time, and the effect of effectively promoting antigen tumors and far-end tumors through multifunction synergism is achieved. Meanwhile, the drug-loaded nanoparticles loaded on the surface of the engineering probiotics can form a slow-release carrier, so that the onset time of the drug is prolonged, and the bioavailability of the drug is improved; the ICD effect is induced, and the conventional cytotoxic effect is converted into the immune activation effect, so that the systemic toxicity caused by the application of large-dose chemotherapeutic drugs is avoided, and the immune activation function of bacteria is retained. The engineering probiotic preparation process is simple and efficient, the whole process is synthesized in a water phase, and the safety is high.

The invention discloses in-situ drug-loaded synergistic treatment gel P-GFe-coated Gel as well as a preparation method and application thereof, and belongs to the field of biological medicines. By integrating the photo-thermal characteristics of mesoporous polydopamine (MPDA), the CDT efficiency of Fe, the TME regulation effect of glucose oxidase (GOx) and the in-situ delivery capacity of protein hydrogel, PTT / CDT synergistic treatment is achieved, and the problems that in existing tumor treatment, targeting is insufficient, the curative effect is limited by TME, and systemic toxicity is high are solved. The preparation technology is simple and mild, raw materials are easy to obtain, large-scale production can be achieved, and wide application prospects are achieved in clinical treatment of malignant tumors such as breast cancer.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The present application relates to cytokine-based bioactivatable drugs and methods of use thereof. The present invention provides a bioactivatable drug construct platform based on cytokines, aimed at reducing systemic toxicity, enabling proteins and cytokines, such as IL-15 and IL-2, to have a broader therapeutic use in the treatment of cancer, autoimmune diseases, inflammatory diseases, viral infections, transplantation and other disorders. The invention relates to a bioactivator comprising a tissue or disease site targeting portion D1 domain, a bioactivatable portion D2 domain and a shielding portion D3 domain. The active moiety of VitoKine remains inert until it is locally activated by an upregulated protease in diseased tissue, which limits binding of the active moiety to receptors or targets in the periphery or on the cell surface of non-diseased cells and tissues, prevents pathway over-activation and reduces undesirable "extracorporeal" "in-target" toxicity. Prior to protease activation, the inertness of the VitoKine active moiety significantly reduces potential antigen or target silencing, extends in vivo half-life and improves biodistribution, bioavailability and therapeutic efficacy.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

The invention belongs to the technical field of biological medicines, and particularly provides an ALO-coated F127-MOF nano-composite as well as a preparation method and application thereof. According to the ALO (at) F127-MOF nano compound, UiO-66-NH2 MOF with a pluronic F-127 coating is used as a nano carrier, and aloperine is loaded on the nano carrier. The nano compound is used for treating ALI, the solubility, stability and bioavailability of the traditional Chinese medicine aloperine are effectively improved, and the synergistic effect of sustained release of aloperine, ROS neutralization and effective targeting is achieved. The aerosolization-based delivery approach ensures better oxygenation, lower systemic toxicity, and better pulmonary deposition. The invention provides a new treatment method for noninvasive acute lung injury treatment.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention discloses an application of an engineered mRNA (messenger Ribonucleic Acid) medicine for coding COL3A1 protein in resisting skin photoaging. According to the method, accurate rational design and optimization are carried out on the 5'untranslated region (UTR) of the hCOL3A1 mRNA, so that the translation efficiency and the protein yield of the hCOL3A1 mRNA are greatly improved, the expression level of the hCOL3A1 target protein far beyond the conventional sequence in vivo and in vitro is realized, and the type III collagen is efficiently and endogenously synthesized in skin cells. Experimental results show that the engineered mRNA can effectively reduce the skin oxidative stress level, inhibit cell aging and promote endogenous synthesis and deposition of corium layer collagen, so that the barrier function of photoaged skin is remarkably improved, the dermis thickness is increased, the tissue structure is repaired, and systemic toxicity or immune side effects are not observed. The invention provides a novel strategy with high efficiency and safety for resisting skin photoaging.

An ABT-263-loaded drug delivery system comprises a liposome and elemental gold, ABT-263 is loaded in the liposome, and the liposome is coated with the elemental gold to form a gold shell (Lipo-atABT263-atAu). Through verification, the senescent cell scavenger (ABT-263) and the golden shell liposome are integrated together to achieve the purposes of sensitizing radiation and continuously releasing drugs. In in-vitro experiments, the Lipo-ABT263-coated Au enhances cell apoptosis induced by radiation therapy, eliminates radiation-induced senescence tumor cells, and inhibits the tumor promoting effect of senescence-related secretion phenotypes. In an animal model, a drug delivery system remarkably inhibits tumor growth, skin fibrosis induced by radiotherapy is relieved through targeted aging fibroblasts, and systemic toxicity is not shown.

The invention provides a subdural hematoma targeted drug delivery system, a preparation method thereof and a pharmaceutical preparation, and belongs to the technical field of targeted drugs. The targeted drug delivery system is a drug-loaded liposome, and the drug-loaded liposome comprises a drug active substance and a liposome carrier loaded with the drug active substance; the liposome carrier is prepared from the following components: cholesterol, lecithin, DSPE-PEG (Distearoyl Phosphate Polyethylene-Polyethylene Glycol) and DSPE-PEG-CLTX. The targeted drug delivery system provided by the invention is spherical, small and uniform in particle size, negatively charged on the surface and good in serum stability, can deliver the drug to the subdural hematoma part in a targeted manner, reduces systemic toxicity of the drug, inhibits pyroptosis, relieves inflammatory response, promotes hematoma absorption and meningeal lymphatic vessel drainage, and has a good application prospect. And the purpose of accurate treatment is achieved.

The invention discloses a gene therapy nose drop for preventing and / or treating coronavirus as well as preparation and application of the gene therapy nose drop, and belongs to the technical field of biological medicines. The nose drop comprises a reagent A and a reagent B. The reagent A is a nano-gene therapy drug solution connecting a self-assembled composite nano-material carrier and a targeted nucleic acid cleavage system through a click reaction, and the cleavage system comprises endonuclease molecules and an hpDNA oligonucleotide probe set. The hpDNA probe can target a coronavirus N gene conserved sequence and a host cell CtslmRNA at the same time through stem-loop structural design, can cut virus RNA to inhibit replication of the virus RNA, and can block the activation process of virus spike protein; the reagent B is an inhalable preparation of an anti-inflammatory chemical drug, and the drug absorption efficiency is remarkably improved by regulating inflammatory reaction. The nose drop can efficiently prevent and treat coronavirus infection and respiratory tract complications caused by the coronavirus infection through a triple mechanism of'gene editing-host regulation-anti-inflammatory treatment 'in combination with the advantage of nasal local administration, and has the obvious characteristics of high bioavailability and low system toxicity.

The invention provides a traditional Chinese medicine composition for treating alopecia areata and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 10 to 30 parts of radix rehmanniae recen, 10 to 30 parts of radix rehmanniae preparata, 10 to 30 parts of caulis spatholobi, 10 to 30 parts of caulis polygoni multiflori, 30 to 50 parts of radix astragali, 10 to 20 parts of rhizoma chuanxiong, 10 to 30 parts of radix paeoniae alba, 5 to 20 parts of rhizoma gastrodiae, 5 to 20 parts of cordyceps sinensis, 10 to 30 parts of herba ecliptae, 10 to 30 parts of mulberry and 5 to 20 parts of fructus chaenomelis. The effect is stronger, and no side effect exists. The tincture prepared by the invention is a pure external preparation without systemic toxicity, has no side effects such as hirsutism and skin atrophy after long-term use, and is especially suitable for sensitive scalp patients.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

The application discloses a new use of androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, namely, application of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in preparation of a medicine for treating lymphoma. 50 The IC value of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in the SR cell line is detected by a CCK-8 method, and the cytotoxicity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione on human umbilical vein endothelial cells Huvce and human immortalized keratinocytes Hacat is detected, in the body, the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione significantly inhibits tumor growth and shows good biological safety and no systemic toxicity; TUNEL staining, gamma-H2AX staining and neutral comet experiment prove that the compound of the application inhibits the growth of SR by causing serious damage to DNA, the application not only adds the diversity of the biological activity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, but also provides a new direction for developing a new medicine for treating lymphoma.